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Evaluation of the effect of serum antibody abundance
against bovine coronavirus on bovine coronavirus
shedding and risk of respiratory tract disease in beef
calves from birth through the first five weeks in a
feedlot
OBJECTIVE
To evaluate the effect of serum antibody abundance against bovine coronavirus (BCV) on BCV shedding and risk of bovine respiratory disease (BRD)
in beef calves from birth through the first 5 weeks in a feedlot.

Aspen M. Workman phd
Larry A. Kuehn phd
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ANIMALS
890 natural-service crossbred beef calves from 4 research herds.
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PROCEDURES
Serial blood samples for measurement of serum anti-BCV antibody abundance by an ELISA and nasal swab specimens for detection of BCV and
other viral and bacterial BRD pathogens by real-time PCR methods were
collected from all calves or subsets of calves at predetermined times from
birth through the first 5 weeks after feedlot entry. Test results were compared among herds, over time, and between calves that did and did not
develop BRD. The associations of various herd and calf factors with test
results were also evaluated.
RESULTS
At the calf level, serum anti-BCV antibody abundance was not associated
with BCV shedding, but BCV shedding was positively associated with BRD
incidence before and after weaning. The mean serum anti-BCV antibody
abundance at weaning for a group of calves was inversely related with the
subsequent incidence of BRD in that group; however, the serum anti-BCV
antibody abundance at weaning for individual calves was not predictive of
which calves would develop BRD after feedlot entry.
CONCLUSIONS AND CLINICAL RELEVANCE
Results indicated that serum anti-BCV antibody abundance as determined
with ELISA were not associated with BCV shedding or risk of BRD in individual beef calves from birth through the first 5 weeks after feedlot entry.
(Am J Vet Res;78:1065–1076)

B

ovine respiratory disease is a serious health and
economic problem for dairy and beef cattle industries worldwide.1,2 This disease complex is frequently
characterized by a primary viral infection in combination with stress, which suppresses the host’s immune system, damages the epithelium of the respiratory tract, and allows opportunistic bacteria such as
ABBREVIATIONS
BCV
Bovine coronavirus
BHV1
Bovine herpesvirus-1
BRD
Bovine respiratory disease
BRSV
Bovine respiratory syncytial virus
BVDV
Bovine viral diarrhea virus
BVDV1
Bovine viral diarrhea virus type 1
BVDV2
Bovine viral diarrhea virus type 2
Ct
Cycle threshold
MLV
Modified-live virus
PI3
Parainfluenza-3 virus
RT
Real-time
USMARC US Meat Animal Research Center

Mannheimia haemolytica, Pasteurella multocida,
Histophilus somni, and Mycoplasma bovis to infect
the lungs.3–5 The major viral pathogens associated
with BRD include BVDV, BRSV, BHV1, and PI3.6,7 Alterations in innate defenses, leukocyte recruitment to
the lungs, and production of proinflammatory cytokines culminate in the pathological lesions associated
with BRD.3 Although intervention strategies such as
vaccination and metaphylactic or therapeutic administration of antimicrobials are commonly used to prevent and treat respiratory tract disease in cattle, the
incidence of BRD remains high.
Within the past decade, BCV has been identified
as another important contributor to BRD.8 Bovine
coronavirus is ubiquitous in cattle populations worldwide and was initially associated with outbreaks
of enteric disease. It is now recognized to have an
etiologic role in 3 distinct clinical syndromes (diarrhea in calves, hemorrhagic diarrhea in adult cattle
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[winter dysentery], and respiratory tract disease in
cattle of all ages).8 Both killed virus and MLV vaccines
are available to control enteric disease in calves and
can be administered to calves at birth or to pregnant
cows to induce production of anti-BCV antibodies
in colostrum. Although all BCV isolates are believed
to belong to a single serotype,8–12 results of a 2013
study13 suggest that there may be differences in seroreactivity between strains isolated from the respiratory tract and a commonly used enteric reference
strain. However, there currently is no BCV vaccine
licensed in the United States to aid in the prevention
of BRD.8
Despite the fact that BCV has been associated
with respiratory tract infections in cattle of all ages,
its role in the pathogenesis of BRD in cattle at various
production stages remains unclear. Most research on
the association between BCV and BRD has involved
feedlot cattle. Shedding of BCV in the absence of
other important respiratory tract pathogens has been
observed in cattle with naturally occurring BRD,14,15
and BCV has been isolated from pneumonic lungs
alone or in combination with other respiratory tract
pathogens.7,14–18 Results of multiple studies14,19–23 indicate that cattle with high anti-BCV antibody titers at
feedlot entry are less likely to shed BCV and develop
BRD than are cattle with low anti-BCV antibody titers at feedlot entry. However, it is not uncommon for
apparently healthy feedlot cattle to shed BCV,14,21,23,24
which raises questions about the respective associations of anti-BCV antibody titer and BCV shedding
with the risk of BRD in feedlot cattle.
Compared with the information known about
feedlot cattle, much less is known about the relationship between BCV and BRD in preweaned beef
calves. Dairy calves, even those with fairly high passively (colostrum) or actively (vaccination) acquired
anti-BCV antibody titers, can shed BCV during the
first week after birth, and recurrent shedding of BCV
by apparently healthy dairy calves is common, which
suggests that many BCV infections are not associated
with disease.25,26 To our knowledge, a comprehensive
study to evaluate BCV shedding and anti-BCV antibody titers in preweaned beef calves (a population
for which the risk of BRD differs substantially among
both individual animals and herds over time) has not
been conducted. Thus, the literature is lacking with
regard to a temporal evaluation of BCV shedding, humoral immunity to BCV, and the risk for development
of BRD throughout the entire production cycle of
beef cattle. The purpose of the study reported here
was to evaluate the effect of serum anti-BCV antibody
abundance on BCV shedding patterns and the incidence of BRD in beef calves from birth through the
first 5 weeks in a feedlot.

Materials and Methods
Animals

Eight hundred ninety natural-service crossbred beef calves born during April and May 2014
1066

were monitored from birth to the end of their fifth
week in a feedlot. All study calves originated from 4
herds that were managed in separate locations at the
USMARC. Each of those 4 herds contained additional
calves that were not enrolled in the study. Herds 1
and 2 consisted of calves that were born as a result
of artificial insemination or natural service, whereas
herds 3 and 4 consisted of calves that were born as
a result of natural service only. Only natural-service
calves were enrolled in the study because calves that
were born as a result of artificial insemination were
enrolled in another study. All calves were managed
in the same manner regardless of whether they were
enrolled in the study reported here. The 4 herds did
not have fence-line contact, so there was no direct
pathogen transmission among herds. All experimental protocols were approved by the USMARC Institutional Animal Care and Use Committee (approval
Nos. 5438-31000-082-04 and 3040-32000-031-07).

Vaccination schedule and calf processing

The cows (dams) in all 4 herds received an
MLV vaccine-bacterin combination producta that
contained antigens of BHV1, BVDV1, BVDV2, PI3,
BRSV, and bacterins for Campylobacter fetus and
5 serovars of Leptospira spp prior to breeding
(approx June) annually. The dams were also vaccinated against enteric pathogens approximately 30 days
before the beginning of calving season. That vaccineb
contained killed strains of bovine rotavirus and BCV,
a K99 Escherichia coli bacterin, and Clostridium
perfringens type C toxoid to enhance the production
and secretion of antibodies against those pathogens
into the colostrum and aid in the prevention of diarrhea in calves.
Calves at approximately 20 to 70 days of age (June
[same time as dams received prebreeding vaccine])
received an initial vaccination with an MLV vaccinebacterin combination productc that contained antigens of BHV1, BVDV1, BVDV2, PI3, BRSV, and M haemolytica and a multivalent bacterin-toxoid productd
intended to protect animals against disease caused by
Clostridium chauvoei, Clostridium septicum, Clostridium novyi, Clostridium sordellii, C perfringens
types C and D, and Moraxella bovis. Calves at 111 to
161 days of age (approx 21 days prior to weaning [ie,
preconditioning]) received a booster of the respiratory
vaccinec and another multivalent clostridial vaccinee
intended to protect animals against disease caused by
C chauvoei, C septicum, Clostridium haemolyticum, C novyi, C sordellii, and C perfringens types
C and D. Calves at approximately 130 to 190 days of
age (weaning and feedlot entry) received another respiratory vaccinef that contained antigens of BHV1,
BVDV1, BVDV2, PI3, and BRSV.
Calves were weaned between September 24
and October 3, 2014, and moved from their herds of
origin to a feedlot where they were processed and
commingled in 14 pens, each of which had capacity
for approximately 70 calves. Calves were allocated
to pens such that each pen contained the same pro-
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portion of calves from each of the 4 herds of origin.
That method of allocation was chosen to maximize
exposure among calves from all 4 herds and simulate
the commingling of calves that occurs at commercial
feedlots.
Over the next 5 weeks, calves with suspected
BRD were removed from each pen for sample collection and treated in accordance with the standard operating procedure established for cattle maintained
at the USMARC. Diagnosis of BRD was made on the
basis of the presence of clinical signs such as lethargy, anorexia, abnormal breathing, nasal and ocular
discharge, and pyrexia. Calves were treated at the discretion of feedlot staff and the attending veterinarian,
all of whom remained unaware of (were blinded to)
the herd of origin for each calf at the time of BRD
diagnosis. All adverse health events and treatments
were recorded for each study calf so that associations between BRD and other comorbidities could be
evaluated.

Sample collection procedures

A blood sample (approx 9 mL) for plasma acquisition was collected between 18 and 48 hours after
birth from a small subset (n = 34) of calves for which
both birth and the first nursing episode were observed. A blood sample (approx 9 mL at initial vaccination and 25 mL at preconditioning and weaning)
for serum acquisition and nasal swab specimens were
collected from all 890 calves at the time of each vaccination (initial vaccination, preconditioning, and
weaning). Those 3 sample acquisition times were selected to eliminate additional stress associated with
excessive handling because calves were already being handled at those times for routine processing and
vaccination.
Additional blood samples (approx 9 mL) and nasal swab specimens were obtained from each calf removed from a pen because of suspected BRD (cases;
n = 67) as well as apparently healthy calves (controls;
109). Two controls were selected for sample collection from each pen on a weekly basis during the first
4 weeks after feedlot entry. Because of a low number
of cases in the fifth week, controls were selected only
from the pens with cases. Controls were selected by
use of a convenience method, rather than a randomized sampling method, to prevent or minimize stress
associated with sorting needed to remove specific
calves. Notches were made in the ear tags of calves
treated for BRD as well as control calves to prevent
those calves from being selected as controls at future
sampling dates.
Blood samples were obtained by jugular venipuncture with an 18-gauge needle at 18 to 48
hours after birth and initial vaccination and with a
16-gauge needle at all sample acquisition times thereafter. Blood samples were centrifuged at 1,650 X g
at 4°C for 25 minutes. Then, the plasma or serum
from each sample was harvested and stored at –80°C
until analysis.

Nasal swab specimens were obtained by passing
2 sterile 6-inch-long cotton-tipped swabs into each
nostril to swab the nasopharyngeal region. For each
calf during each sample acquisition time, 1 nasal
swab specimen from each nostril was obtained and
placed into a cryovial that contained 1 mL of transport medium (buffered peptone water with 12% glycerol). Vials were snap-frozen in liquid nitrogen and
stored at –80°C until analysis.

Detection of viral pathogens by use
of RT-PCR assay

Real-time PCR methods were used to detect respiratory viruses (BHV1, BVDV, BCV, and BRSV) in
nasal swab medium that was used for transport and
storage of nasal swab specimens. Viral shedding was
determined for 60 calves that were randomly selected by means of a random number generator from
each of the 4 herds at each of the 3 routine sample
acquisition times (initial vaccination, preconditioning, and weaning). That sample size was selected
because it was calculated to have a 95% probability
for detection of at least 1 infected animal if the true
prevalence of viral shedding in the herd at the sample
acquisition time was at least 5%.27 Viral shedding was
also determined for cases and controls on the basis
of disease status and sample collection date. Briefly,
pools consisting of nasal swab medium from 5 calves
were created on the basis of herd of origin at each
routine sample acquisition time as well as on the basis of disease status (case or control) and sample collection date.
Each pool contained 100 µL of nasal swab medium from each of the 5 designated calves. From each
pooled sample, RNA was extracted by use of a phenol and guanidine isothiocyanate reagent,g and DNA
was extracted with a silica membrane–based nucleic
acid purification kit.h Then, an RT-PCR assay was performed to detect the major viral pathogens associated
with BRD (BHV1, BRSV, BVDV, and BCV). Primers
and probes used for the assay were the same as those
described in other studies.28–31 For each sample analyzed, cyclic amplification was conducted on a 25-µL
reaction solution containing 2.5 µL each of extracted
RNA and DNA, 4.5mM magnesium chloride, 400µM
of deoxyribonucleotide triphosphate, 0.4µM concentration of each primer, 0.2µM concentration of each
probe, and 1 µL of an enzyme mixi with reverse transcriptase and a hot-start Taq polymerase. Cycling
conditions included reverse transcription at 50°C for
30 minutes, inactivation of the reverse transcriptase
enzyme and activation of the Taq polymerase at 95°C
for 15 minutes, and 40 cycles of 94°C for 30 seconds,
55°C for 60 seconds, and 72°C for 60 seconds. Positive, negative, no-template, and extraction control
samples were included in each assay. Samples with
a Ct value < 40 were considered to have positive
results for the virus of interest. For pooled samples
that yielded positive results for a particular virus, the
RT-PCR assay was repeated on individual nasal swab
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medium from each of the 5 calves that contributed to
the pooled sample to identify the calf or calves that
were shedding the virus of interest.

Detection of bacterial pathogens
by RT-PCR assay

Samples of nasal swab medium collected from
cases (calves with BRD) and controls during the first
5 weeks after feedlot entry were sent to the University of Nebraska-Lincoln Veterinary Diagnostic Center
for detection of M haemolytica, P multocida, H somni, and M bovis by use of multiplex RT-PCR methods
that have been validated for nasal swab specimens
and lung tissue matrices obtained from cattle.j This
RT-PCR assay was performed on individual samples
(ie, samples were not pooled).

Detection of anti-BCV antibodies

For each of the 240 calves evaluated for BCV
shedding at initial vaccination and weaning, serum
anti-BCV antibody abundance was measured by use
of a commercially available indirect antibody ELISA k
in accordance with the manufacturer’s instructions.
Serum anti-BCV antibody abundance was also measured in samples collected at initial vaccination and
weaning for the 67 cases and 109 controls evaluated
during the first 5 weeks after feedlot entry and in
samples collected from birth through weaning for a
small subset of calves from herds 3 (n = 21) and 2 (13)
that did and did not, respectively, have evidence of
BCV infection in preweaned calves. Briefly, test plates
were assessed at a wavelength of 450 nm with a computer-linked ELISA plate reader.l Optical density of
the tested sample was divided by the optical density
of the positive control sample provided in the kit to
calculate the anti-BCV antibody percentage positivity for the tested sample. Samples with a percentage
positivity < 10 were considered negative for anti-BCV
antibodies (seronegative), whereas those with a percentage positivity ≥ 10 were considered positive for
anti-BCV antibodies (seropositive). A percentage positivity > 100 could be obtained if the concentration of
anti-BCV antibodies in the tested sample was greater
than that in the positive control sample provided in
the kit. A dilution series for the positive control sample was used to determine the assay limit of linearity
because the linear range for measurement of antiBCV antibodies was not provided by the manufacturer. Results indicated that the percentage positivity of
the positive control sample had a good linear range
from 10 to 100. When measured values were compared with expected values, the linearity equation
was Y = 1.657X – 0.08916, with R2 = 0.999. All test
samples with results greater than that linear range
were diluted and retested. The adjusted percentage
positivity was calculated as the dilution factor of the
sample multiplied by the percentage positivity, and
that value was accepted as the relative anti-BCV antibody abundance.
1068

Statistical analysis

Individual calves were the experimental unit for
all analyses. Two-way contingency tablesm were created, and χ2 tests were used to assess the respective
associations between the development of BRD during
the first 5 weeks after feedlot entry (case or control
status) and BCV shedding and the presence of specific bacterial pathogens in the nasopharynx. The
respective associations between serum anti-BCV antibody ELISA results and herd of origin or case status
were evaluated by use of a 1-way ANOVA followed
by t tests for pairwise comparisons only if the overall F test was significant. Separate linear regression
models were developed for the dependent variables
of weaning age and weaning weight. Both models
included fixed effects for herd of origin, case status,
and the interaction between herd of origin and case
status. Logistic regression analysis was used to determine the effect of herd on case status. All ANOVA and
regression analyses were performed with a commercially available statistical software program.n Values of
P < 0.05 were considered significant for all analyses.

Results
Calves

The number of calves enrolled in the study from
each herd, median dam parity within each herd, and
mean ± SD weaning age and weight for the study
calves were summarized (Table 1). Although cows in
all 4 herds were exposed to bulls during the same 60day period, the time during that period at which the
study calves were conceived differed among herds.
Thus, the mean weaning age and weaning weight of
study calves differed among herds. Of the 890 calves
enrolled in the study, 4 were excluded prior to weaning because of injury or death, although none of the
conditions were known to be related to infectious
disease.

Respiratory virus shedding and BRD
incidence prior to feedlot entry

Shedding of each of 4 respiratory viruses (BHV1,
BVDV, BRSV, and BCV) in 60 randomly selected study
calves from each herd was determined at initial vaccination (20 to 70 days old), preconditioning (111 to
161 days old), and weaning (130 to 190 days old). Bovine viral diarrhea virus was not detected in any calf
at any sample acquisition time prior to feedlot entry.
Bovine herpesvirus-1 was detected in 2 calves of herd
4 at weaning; BRSV was also detected in 1 of those
calves. The number of calves from which BCV was detected in nasal swab specimens was summarized (Table 2). Bovine coronavirus was detected in 14 (23%)
calves of herd 3 at initial vaccination and 8 (13%) and
9 (15%) calves of herds 1 and 3, respectively, at weaning. The overall prevalence rate of BCV shedding was
6% (14/240) at initial vaccination, 0% at preconditioning, and 7% (17/240) at weaning, and the overall prevalence rate of BCV shedding prior to feedlot entry was
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Table 1—Descriptive characteristics for 890 natural-service crossbred beef calves born in 4 USMARC herds during April and May
2014 that were monitored from birth to the end of their fifth week in a feedlot to evaluate the effect of serum anti-BCV antibody
abundance on BCV shedding and the incidence of BRD.
Herd
Variable
Total No. of calves
No. of calves enrolled in study
Dam parity
Weaning age (d)
Weaning weight (kg)
No. (%) of study calves
that developed BRD prior
to feedlot entry
No. (%) of study calves
that developed BRD
during the first 5 wk after
feedlot entry

1

2

3

4

534
138
2.5 (1–4)
146 ± 12a,b
203 ± 23a
2 (1.5)

624
413
5.2 (2–9)
148 ± 18a
211 ± 31a
0 (0)

241
226
7.3 (4–11)
162 ± 17c
236 ± 33b
25 (11)

116
113
6.0 (4–8)
158 ± 15b,c
236 ± 31b
0 (0)

3 (2)

51 (12)

12 (5)

4 (4)

Values represent the mean ± SD or median (range) unless otherwise specified. A diagnosis of BRD was made on the basis of the presence of
lethargy, anorexia, abnormal breathing, nasal and ocular discharge, and pyrexia.
a–cWithin a row, values with different superscript letters differ significantly (P < 0.05).

Table 2—Number (percentage) of calves from which BCV was detected in nasal swab specimens at initial vaccination (20 to 70
days old), preconditioning (111 to 161 days old), and weaning (130 to 190 days old).
Herd		
Sample acquisition time
Initial vaccination
Preconditioning
Weaning
Total

1
0 (0)
0 (0)
8 (13)
8 (4)

2

3

4

Total

0 (0)
0 (0)
0 (0)
0 (0)

14 (23)
0 (0)
9 (15)
23 (13)

0 (0)
0 (0)
0 (0)
0 (0)

14 (6)
0 (0)
17 (7)
31 (4)

For each herd at each specified sample acquisition time, nasal swab specimens from 60 arbitrarily selected calves were assayed by use of RTPCR assay for determination of BCV shedding.

4% (8/180) for herd 1, 0% for herd 2, 13% (23/180) for
herd 3, and 0% for herd 4. The incidence of BRD (defined as the presence of lethargy, anorexia, abnormal
breathing, nasal and ocular discharge, and pyrexia)
in calves prior to feedlot entry differed among the 4
herds and ranged from 0% (herds 2 and 4) to 11% (herd
3). The incidence rate of BRD in calves prior to feedlot
entry for herd 3 (25/226 [11%]) was significantly greater than that for herd 1 (2/138 [1.5%]). None of the 27
calves that developed BRD prior to feedlot entry had
comorbidities such as diarrhea, and only 3 calves were
treated for diarrhea prior to feedlot entry.

Respiratory virus shedding and BRD
incidence during the first 5 weeks after
feedlot entry

Of the calves enrolled in the study, 70 (7.9%) developed BRD during the first 5 weeks after feedlot
entry (cases). The incidence rate of BRD in calves
during the first 5 weeks after feedlot entry differed
among the 4 herds of origin. The incidence rate of
BRD for herd 2 (51/413 [12%]) was significantly greater than that for herds 1 (3/138 [2%]), 3 (12/226 [5%]),
and 4 (4/113 [4%]).
Of the 70 cases, 39 (55.7%) were steers and 31
(44.3%) were heifers. The cases were distributed fairly
equally among the 14 pens, with at least 1 BRD case

identified in 11 pens during the first week after feedlot
entry (Supplementary Table S1, available at avmajournals.avma.org/doi/suppl/10.2460/ajvr.78.9.1065).
Although controls were selected on the basis of convenience, neither the mean weaning age nor mean weaning weight differed significantly between cases and controls regardless of whether herd of origin was or was
not controlled (data not shown), which suggested that
the case and control populations were well matched.
Sixty-seven of the 70 BRD case samples were
available for analysis. Bovine viral diarrhea virus was
detected in 1 case, and sequence analysis of the 5′ untranslated region of the isolated virus revealed that it
was a BVDV1a strain that was 98% homologous to the
NADL strain used in the administered MLV vaccine
(data not shown). Bovine herpesvirus-1 and BRSV
were not detected in any calf during the first 5 weeks
after feedlot entry.
Bovine coronavirus RNA was detected in nasal
swab specimens from 65 of 67 (97%) cases and 64 of
109 (59%) controls (Table 3) and was detected in all
cases and controls sampled during the first 2 weeks after feedlot entry. However, for calves that had positive
results for BCV (Ct < 40) by use of the RT-PCR assay, the
mean Ct value was significantly (P < 0.001) lower for
cases than for controls during the first week after feedlot entry (Figure 1), which suggested that cases were
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Table 3—Number of BRD case and control calves from which BCV was detected in nasal swab specimens during each of the first
5 weeks after feedlot entry.
Herd
		

1

2

3

4

Total

Time after		
No.		 No.		 No.		 No.		 No.
feedlot
BRD
positive
No.
positive
No.
positive
No.
positive
No.
positive
entry (wk) status
for BCV
sampled
for BCV
sampled
for BCV
sampled
for BCV
sampled
for BCV
1
2
3
4
5
Total

Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control

2
1
0
4
0
0
0
0
0
0
2
5

2
1
0
4
0
4
1
5
0
0
3
14

19
13
13
8
7
4
8
6
2
0
49
31

19
13
13
8
7
6
8
12
2
3
49
42

2
10
2
8
3
0
2
0
1
0
10
18

2
10
2
8
3
11
3
5
1
1
11
35

1
2
2
6
0
0
0
2
1
0
4
10

1
2
2
6
0
5
0
4
1
1
4
18

24
26
17
26
10
4
10
8
4
0
65
64

No.
sampled
24
26
17
26
10
26
12
26
4
5
67
109

Bovine coronavirus was detected by means of RT-PCR assay methods, and samples with a Ct value < 40 were considered to have positive results.
See Table 1 for remainder of key.

tive results for BCV during that period originated from
herd 2. In contrast, BCV was detected in 24 of 26 (92%)
cases during weeks 3, 4, and 5, and those BCV-positive
cases originated from all herds, except herd 1. During
the first 5 weeks after feedlot entry, cases were 23 times
(OR, 23; 95% confidence interval, 5 to 142; P < 0.001) as
likely to shed BCV as were controls. However, given that
BCV was detected in all 41 cases and 52 controls evaluated during the first 2 weeks after feedlot entry, weeks
3 through 5 after feedlot entry were analyzed separate
from weeks 1 and 2 after feedlot entry. During weeks 3
through 5 after feedlot entry, cases were 45 times (OR,
45; 95% confidence interval, 8 to 322; P < 0.001) as likely to shed BCV as were controls.
Figure 1—Scatterplots of RT-PCR assay results for calves in
which BCV was detected in nasal swab specimens and that did
(cases; circles) or did not (controls; squares) develop BRD during each of the first 5 weeks after feedlot entry. At feedlot entry,
886 natural-service crossbred beef calves from 4 herds of origin
were commingled and allocated among 14 pens such that each
pen contained the same proportion of calves from each herd.
Cases were defined as calves with clinical signs of BRD, including lethargy, anorexia, abnormal breathing, nasal and ocular discharge, and pyrexia. Controls were apparently healthy calves,
and 2 controls were selected on the basis of convenience from
each pen weekly for sample collection. Cases and controls were
excluded from future sampling; thus, each case and control is
represented only once in the figure. Results were reported as
Ct values. The Ct value is inversely associated with the amount
of BCV RNA detected; therefore, the lower the Ct value, the
greater the amount of BCV RNA in the sample. Samples with a
Ct value < 40 were considered to have positive results for BCV.
For each scatterplot, the horizontal line represents the mean
and the vertical line delimits the SD. *Within a given week, the
mean Ct value differs significantly (P < 0.05) between cases and
controls.

shedding a greater amount of BCV in their nasal secretions than controls during that week. During weeks
3, 4, and 5 after feedlot entry, BCV was not detected
in any control that originated from herds 1 and 3 but
was detected in 10 of 21 controls that originated from
herd 2 and 2 of 10 controls that originated from herd
4. Thus, the majority (10/12) of controls that had posi1070

Bacterial shedding and BRD incidence
during first 5 weeks after feedlot entry

The numbers of cases and controls from which
M haemolytica, P multocida, H somni, and M bovis
were detected in nasal swab specimens during each
of the first 5 weeks after feedlot entry were summarized (Table 4). During week 4 after feedlot entry,
the proportion of cases (11/12 [92%]) that had positive results for M bovis was significantly (P = 0.002)
greater than the proportion of controls (8/26 [31%])
that had positive results for M bovis. However, the
proportion of test-positive cases did not differ significantly from the proportion of test-positive controls
for any bacterial species evaluated during any other
week. Additionally, for test-positive calves, the mean
Ct value for cases did not differ significantly from the
mean Ct value for controls for any bacterial species or
week after feedlot entry (Figure 2), which indicated
that, for each bacterial species evaluated, the relative
abundance of bacteria (bacterial load) in the nasopharynx did not differ between cases and controls.

Effect of serum anti-BCV antibody
abundance on BCV shedding

Relative serum anti-BCV antibody abundance
for the calves from each herd that were evaluated
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Table 4—Number of case and control calves for which Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis were detected in nasal swab specimens during the first 5 weeks after feedlot entry.
Time after
feedlot entry (wk)

BRD		
status
No. sampled

1

Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control

2
3
4
5
Total

24
26
17
26
10
26
12
26
4
5
67
109

No. positive
for M haemolytica

No. positive
for P multocida

No. positive
for H somni

8
7
5
12
6
12
7
10
4
2
30 (45)
43 (39)

8
9
6
10
6
17
10
20
4
3
34 (51)
59 (54)

13
9
6
9
5
8
7
7
2
2
32 (48)
35 (32)

No. positive
for M bovis
0
0
2
5
5
4
11*
8
2
1
20 (30)
18 (17)

All bacterial species were detected by means of RT-PCR assay methods, and samples with a Ct value < 40 were considered to have positive
results for the bacterial species of interest. Numbers within parentheses represent the percentage of the total cases or controls.
*Within a week, the proportion of cases that had positive results for the given bacterial species differs significantly (P < 0.05) from the corresponding proportion for controls.
See Table 1 for remainder of key.

Figure 2—Scatterplots of RT-PCR assay results for the cases (circles) and controls (squares) of Figure 1 in which Mannheimia
haemolytica (A), Pasteurella multocida (B), Histophilus somni (C), and Mycoplasma bovis (D) were detected in nasal swab specimens
during each of the first 5 weeks after feedlot entry. For all bacterial species, samples with a Ct value < 40 were considered to
have positive results. See Figure 1 for remainder of key.

for BCV shedding at initial vaccination and weaning
were plotted (Figure 3). At initial vaccination, BCV
shedding was detected in 14 of 60 (23%) calves from

herd 3 but was not detected in any calves evaluated
from the other 3 herds. The calves evaluated from
herd 3 had the highest mean relative anti-BCV anti-
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Figure 3—Scatterplots of the relative serum anti-BCV
antibody abundance for calves that were (squares) or were
not (circles) shedding BCV at initial vaccination (20 to 70
days old; A) and weaning (130 to 190 days old; B). Relative
anti-BCV antibody abundance and BCV shedding were determined for 60 randomly selected calves from each herd at
both initial vaccination and weaning. a–cMean relative antiBCV antibody abundance for herds with different letters
differs significantly (P < 0.05). See Figure 1 for remainder
of key.

body abundance (382), which was significantly greater than that for herds 1 (184) and 2 (254) but did not
differ from that for herd 4 (317). The mean anti-BCV
antibody abundance at initial vaccination for herd 1
was significantly less than that for the other 3 herds,
and that for herd 2 was significantly less than that for
herd 3. Within herd 3, the mean anti-BCV antibody
abundance did not differ significantly (P = 0.65) between calves that were and were not shedding BCV
at initial vaccination.
At weaning, BCV shedding was detected in 8 of
60 (13%) calves from herd 1 and 9 of 60 (15%) calves
from herd 3. Mean relative anti-BCV antibody abundance at weaning was greatest for the calves of herd 4
(115) but did not differ significantly from that for the
calves of herd 3 (106). Mean relative anti-BCV antibody
abundance at weaning was lowest for the calves of
herd 2 (45) and differed significantly from that for the
calves of the other 3 herds. Herd 2 also had the highest proportion of calves that were seronegative for
antibodies against BCV. Mean relative anti-BCV antibody abundance at weaning for the calves of herd 1
1072

Figure 4—Scatterplots of the relative serum anti-BCV antibody abundance at initial vaccination (A) and weaning (B) for
the cases (circles) and controls (squares) of Figure 1. *Mean
relative anti-BCV antibody abundance for herd 2 differed significantly (P < 0.001) from that for each of the other 3 herds.
See Figure 1 for remainder of key.

(89) was significantly greater than that for the calves
of herd 4 but did not differ significantly from that for
the calves of herd 3. At weaning, mean anti-BCV antibody abundance did not differ significantly between
calves that were and were not shedding BCV within
herds 1 (P = 0.22) and 3 (P = 0.37).

Effect of serum anti-BCV antibody
abundance on BRD incidence during the
first 5 weeks after feedlot entry
Within each herd, the mean relative anti-BCV
antibody abundance at initial vaccination and weaning did not differ significantly between cases and
controls. Mean relative anti-BCV antibody abundance
for all calves (cases and controls) did not differ significantly among herds at initial vaccination but was
significantly (P < 0.001) lower for the calves of herd
2, compared with that for the calves from each of the
other 3 herds, at weaning (Figure 4). Within herds,
mean relative anti-BCV antibody abundance at weaning was inversely associated with the proportion of
cases. The incidence of BRD during the first 5 weeks
after feedlot entry was greatest for calves that originated from herd 2 (51/413 [12%]), which also had the
lowest mean relative anti-BCV antibody abundance.
Herd 2 was also the only herd that had calves seronegative for anti-BCV antibodies at weaning (ie, feed-
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lower than that for herd 3 at both initial vaccination (P = 0.001) and weaning (P < 0.001).

Discussion

Figure 5—Scatterplots of the relative serum anti-BCV antibody abundance for a subset of calves from herds 2 (circles;
n = 13) and 3 (squares; 21) that were evaluated at 18 to 48
hours old, initial vaccination, and weaning. Prior to feedlot
entry, BCV shedding was not detected in any of the calves
evaluated from herd 2, but it was detected in 23 of 180 calves
evaluated in herd 3. The subset of calves from herd 3 represented in this figure included 8 calves from which BCV was
detected in nasal swab specimens prior to feedlot entry.
*Within a sample acquisition time, mean relative anti-BCV
antibody abundance differs significantly (P ≤ 0.001) between
the 2 herds. See Figure 1 for remainder of key.

lot entry); 13 (8 cases and 5 controls) of 104 (12.5%)
calves evaluated from herd 2 were seronegative for
anti-BCV antibodies at weaning. When those 13 calves
were removed from the analysis, mean anti-BCV antibody abundance for herd 2 was still significantly (P <
0.001) lower than that for each of the other 3 herds
(data not shown).

Relative anti-BCV antibody abundance
over time in herds with and without
evidence of BCV shedding prior
to feedlot entry
Relative serum anti-BCV antibody abundance
was plotted for a subset of calves from herds 2 (n
= 13) and 3 (21) that were evaluated at all 3 sample
acquisition times prior to feedlot entry (18 to 48
hours old, initial vaccination, and weaning; Figure
5). Prior to feedlot entry, BCV was not detected in
nasal swab specimens from any of the calves evaluated from herd 2 but was detected in nasal swab
specimens from 23 of 180 calves evaluated from
herd 3. The subset of calves evaluated from herd
3 included 8 calves from which BCV was detected in nasal swab specimens prior to feedlot entry.
Relative serum anti-BCV antibody abundance for
samples collected from calves at 18 to 48 hours old
likely reflected passively acquired (maternally derived) anti-BCV antibodies, and the mean relative
anti-BCV antibody abundance did not differ significantly between herds 2 and 3 at that sample acquisition time. However, the mean relative anti-BCV
antibody abundance for herd 2 was significantly

Although there is mounting evidence that BCV is
involved in the etiology of BRD, information regarding the respective temporal relationships between
humoral immunity against BCV and BCV shedding
and the risk for the development of BRD in beef
calves at various times before and after feedlot entry is lacking. Results of the present study indicated
that serum anti-BCV antibody abundance was not associated with BCV shedding; however, BCV shedding
was positively associated with the incidence of BRD.
Also, the mean serum anti-BCV antibody abundance
for a group of calves was inversely related to the subsequent incidence of BRD in that group. However,
serum anti-BCV antibody abundance at weaning for
individual calves within a group was not predictive of
which calves would subsequently require treatment
for BRD.
For the calves of the present study, the rate of
BCV shedding prior to weaning differed among the
4 herds of origin and over time; however, the BCV
shedding pattern was not associated with serum antiBCV antibody abundance. Dams of the calves were
vaccinated with a vaccine containing an enteric BCV
strain 30 days before the start of calving season to
facilitate the passive transfer of anti-BCV antibodies
via colostrum and aid in the prevention of diarrhea
in calves. We hypothesized that BCV-induced disease
outbreaks would occur in preweaned calves when a
certain proportion of that population lost protective
immunity owing to the natural decline of maternally
derived anti-BCV antibodies. However, despite significant differences in the prevalence of BCV shedding
among herds at the initial vaccination (20 to 70 days
old) and weaning (130 to 190 days old) time points,
no association was observed between mean anti-BCV
antibody abundance and prevalence of respiratory virus shedding. Furthermore, within-herd analyses indicated that the mean serum anti-BCV antibody abundance did not differ significantly between calves that
were and were not shedding BCV. These results suggested that the serum anti-BCV antibody abundance
as determined by use of a currently available ELISA
did not accurately predict BCV shedding in individual beef calves prior to weaning and were consistent
with findings of studies25,26 involving preweaned
dairy calves in which subclinical and recurrent BCV
infections, albeit common, are not correlated with serum anti-BCV antibody titers. Differences in the rate
of BCV shedding by preweaned calves among the 4
herds of origin were likely a function of the extent of
exposure those calves had to the virus.
Contrary to serum anti-BCV antibody abundance,
the prevalence of BCV shedding by preweaned calves
in a herd appeared to be positively correlated with
the incidence of BRD in those calves. The BRD incidence rate in preweaned calves was greatest for herds
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1 (2/138 [1.4%]) and 3 (25/226 [11%]), the 2 herds in
which calves shedding BCV were detected. Nasal swab
specimens for pathogen detection were not collected
at the time of BRD diagnosis from preweaned calves;
therefore, it is unknown whether BCV was involved in
the pathogenesis of clinical BRD in those calves. Herdlevel risk factors associated with BRD in preweaned
beef calves include large herd size, incidence rate of
diarrhea in calves, duration of calving season, and introduction of cattle from outside sources.32–34 None of
those factors were associated with the incidence of BRD
in preweaned calves for the USMARC herds involved in
the present study, although the introduction of outside
cattle could not be assessed because those herds are
closed populations. In another study,35 the incidence
of BRD in preweaned calves was negatively associated
with dam parity (ie, calves from young cows were more
likely to develop BRD than calves from older cows),
which the investigators attributed to improvements in
the quality and quantity of colostrum and milk, and
thereby the passive transfer of maternally derived antibodies to calves, as cows age. Interestingly, the herd
with the highest incidence of BRD in preweaned calves
in the present study (herd 3) had the highest median
dam parity. Additionally, mean serum anti-BCV antibody
abundance for calves at 18 to 48 hours old did not differ
significantly between the herds that did (herds 1 and 3)
and did not have (herds 2 and 4) BCV or BRD detected
in preweaned calves, which further suggested that passive transfer of maternally derived anti-BCV antibodies
was not associated with BCV shedding or the risk for
development of BRD. In fact, in the study reported here,
BCV shedding was the only factor evaluated that was
significantly associated with BRD incidence in calves
both before and after weaning.
In the present study, the prevalence of calves
shedding BCV was fairly low prior to weaning, but it
was quite high during the first 5 weeks after feedlot
entry. In fact, BCV was detected in the nasal swab
specimens collected from all calves that developed
BRD (cases) and apparently healthy calves (controls)
evaluated during the first 2 weeks after feedlot entry. This indicated that BCV infection was associated
with both subclinical and clinical disease. However,
the amount of BCV RNA detected in the nasal swab
specimens of cases was significantly greater than that
detected in the nasal swab specimens of controls,
which suggested that disease severity was positively associated with viral load. Results of other studies14,19,21,36–38 indicate that the rate of seroconversion
to BCV can be as high as 100% in beef calves during
the first few weeks after feedlot entry, which suggests that BCV transmission among calves is common
at feedlot entry. In the present study, BCV shedding
remained a significant factor in the development of
BRD in calves during weeks 3 through 5 after feedlot entry. Furthermore, during weeks 3 through 5
after feedlot entry, M bovis was detected in nasal
swab specimens from a significantly greater proportion of cases (18/27 [67%]) than controls (13/57
1074

[23%]), which suggested that the presence of both
BCV and M bovis in the nasopharynx in conjunction
with other stressors (eg, weaning and changing pens)
may have contributed to the development of BRD in
calves during that period.
The role of BCV in the development of BRD
in calves was further supported by the fact that,
in the present study, the mean serum anti-BCV antibody abundance for a group of calves at weaning
was inversely associated with the incidence of BRD
for those calves during the first 5 weeks after feedlot entry. Mean serum anti-BCV antibody abundance
at weaning for the calves of herd 2 was significantly
lower than that for the calves of the other 3 herds
(Figure 4), and calves of herd 2 had the highest incidence of BRD during the first 5 weeks after feedlot
entry. As previously mentioned, mean serum antiBCV antibody abundance for calves at 18 to 48 hours
old did not differ among the 4 herds; therefore, the
differences observed at weaning were most likely
the result of differences in BCV exposure rather than
differences in passive transfer of maternally derived
antibodies. The findings of the present study were
consistent with results of other studies14,19–23 that
have indicated BCV infection before weaning is protective against development of BRD after weaning
and that calves with high serum anti-BCV antibody
abundance at feedlot entry are less likely to develop
BRD than calves with low serum anti-BCV antibody
abundance. However, in the study reported here,
contrary to other studies,14,21 the serum anti-BCV antibody titer at weaning for individual calves was not
predictive of which calves would be treated for BRD
after feedlot entry.
The reasons serum anti-BCV antibody abundance was not associated with BCV shedding or BRD
incidence in preweaned and weaned beef calves in
the present study are unknown. The ELISA used to
measure anti-BCV antibodies in the present study
detected total reactive rather than neutralizing
antibodies. It is also possible that anti-BCV antibodies generated in response to a natural infection might
have had a weak protective effect against viral replication, which would protect against the development of clinical signs of disease but not against virus
shedding. That would be consistent with results of
other studies, which indicate that subclinical BCV
infections14,21,23–26 and recurrent or intermittent25,26
shedding of BCV are common. It also may suggest
a lack of long-term protective immunity after natural infection.8 The role of cell-mediated immunity in
the mediation of viral shedding in calves with BRD is
poorly characterized. It is possible that cell-mediated
immune responses may correlate with BCV shedding
and the development of BRD better than serum antiBCV antibody abundance. Finally, BCV shedding and
the serum anti-BCV antibody abundance were evaluated in the calves of this study fairly infrequently from
birth through the first 5 weeks after feedlot entry.
Thus, we based our results on a series of snapshots
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in time. Calves that were not identified as BCV shedders may have shed BCV between sample acquisition
times, which might have masked the effect of serum
anti-BCV antibody abundance on BCV shedding. Future studies should be designed to distinguish between these possibilities and determine the best immune correlates of protection for BCV infection.
In the present study, detection of BCV in nasal swab
specimens obtained from preweaned beef calves was
associated with the incidence of BRD in those calves
before and after weaning. Also, the mean anti-BCV
antibody abundance at weaning for a group of calves
was inversely associated with the incidence of BRD
for those calves after feedlot entry, which suggested
that calves infected with BCV prior to weaning were
protected against BRD after weaning and feedlot
entry. However, the serum anti-BCV antibody abundance at weaning for individual calves was not predictive of which calves would be treated for BRD
after feedlot entry. Although BCV shedding (which
was presumably indicative of infection) was not associated with death in the present study, BCV infection can have adverse effects on calf health and
well-being as well as feedlot productivity owing to a
decrease in weight gain8,20 and increase in veterinary
care costs for affected calves. Thus, generation of immunity against BCV in calves prior to feedlot entry
should decrease the incidence of BRD and associated
adverse animal health issues and production losses.20
Further studies are necessary to elucidate the role of
BCV in the pathogenesis of BRD in beef cattle at various stages of the production cycle. Such information
is necessary to guide BCV vaccine development and
control strategies.
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